EC nod for merger of Mylan and Pfizer’s Upjohn division
The decision ensures that the merger between Mylan and Upjohn does not harm competition
Read More
Tag: Mylan
NHS set to save record £300 million on highest drug spend
The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug.
Read More
UK launch for Mylan, Biocon insulin glargine biosimilar Semglee
Mylan and Biocon have announced the UK launch of Semglee – an approved biosimilar of reference medicine insulin glargine.
Read More
Pfizer loses landmark second medical use patent case
The UK Supreme Court has ruled against Pfizer in a long-running legal battle over the validity of a second medical use patent protecting pregabalin.
Read More
FDA to reject Mylan’s Advair Diskus generic
Mylan has announced that US regulators are going to reject its generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus.
Read More
US OKs first biosimilar of Amgen’s Neulasta
Mylan and Biocon’s Fulphila has become the first biosimilar of Amgen’s Neulasta to be approved by the US Food and Drug Administration.
Read More
Mylan, Revance link to develop Botox biosimilar
Mylan and Revance Therapeutics have unveiled plans to develop a biosimilar to Allergan’s neuromodulator Botox.
Read More
Mylan launches Copaxone generic in the UK
Mylan has launched in the UK the first generic formulation of Teva’s multiple sclerosis blockbuster Copaxone, offering a potentially cheaper alternative for treatment of relapsing forms of the condition.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
